These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 2828590)

  • 21. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for short-term prognosis in breast cancer.
    Eissa S; Khalifa A; el-Gharib A; Salah N; Mohamed MK
    Anticancer Res; 1997; 17(4B):3091-7. PubMed ID: 9329609
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epidermal growth factor and its receptor as prognostic indicators in Chinese patients with pancreatic cancer.
    Dong M; Nio Y; Guo KJ; Tamura K; Tian YL; Dong YT
    Anticancer Res; 1998; 18(6B):4613-9. PubMed ID: 9891528
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunohistochemical expression of insulin-like growth factor binding protein-3 in invasive breast cancers and ductal carcinoma in situ: implications for clinicopathology and patient outcome.
    Vestey SB; Perks CM; Sen C; Calder CJ; Holly JM; Winters ZE
    Breast Cancer Res; 2005; 7(1):R119-29. PubMed ID: 15642160
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oestrogen receptors revisited: long-term follow up of over five thousand breast cancer patients.
    Hähnel R; Spilsbury K
    ANZ J Surg; 2004 Nov; 74(11):957-60. PubMed ID: 15550082
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intensity of androgen and epidermal growth factor receptor immunoreactivity in samples of radical prostatectomy as prognostic indicator: correlation with clinical data of long-term observations.
    Schäfer W; Funke PJ; Kunde D; Rausch U; Wennemuth G; Stützer H
    J Urol; 2006 Aug; 176(2):532-7. PubMed ID: 16813883
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Estrogen and progesterone receptors in breast cancer: relationships to tumour histopathology and survival of patients.
    Blanco G; Alavaikko M; Ojala A; Collan Y; Heikkinen M; Hietanen T; Aine R; Taskinen PJ
    Anticancer Res; 1984; 4(6):383-9. PubMed ID: 6097159
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Matrix metalloproteinase expression in human breast cancer: an immunohistochemical study including correlation with cathepsin D, type IV collagen, laminin, fibronectin, EGFR, c-erbB-2 oncoprotein, p53, steroid receptors status and proliferative indices.
    Ioachim EE; Athanassiadou SE; Kamina S; Carassavoglou K; Agnantis NJ
    Anticancer Res; 1998; 18(3A):1665-70. PubMed ID: 9673387
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Heparin-binding epidermal growth factor-like growth factor isoforms and epidermal growth factor receptor/ErbB1 expression in bladder cancer and their relation to clinical outcome.
    Kramer C; Klasmeyer K; Bojar H; Schulz WA; Ackermann R; Grimm MO
    Cancer; 2007 May; 109(10):2016-24. PubMed ID: 17394193
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Studies on p53 immunolocalisation in breast cancer and its prognostic significance.
    Meenakshi A; Manoharan V
    Hum Antibodies; 1999; 9(3):171-6. PubMed ID: 10690631
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A new look at the prognostic value of the estrogen, progesterone and epidermal growth factor receptors in breast cancer tissue.
    Skasko E; Paszko Z; Mazur S
    Neoplasma; 2005; 52(1):10-7. PubMed ID: 15739020
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transforming growth factor-alpha, epidermal growth factor receptor, and MiB-1 expression in Barrett's-associated neoplasia: correlation with prognosis.
    Yacoub L; Goldman H; Odze RD
    Mod Pathol; 1997 Feb; 10(2):105-12. PubMed ID: 9127315
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlation of the EGF-receptor with cell kinetic and classical prognostic factors in breast cancer.
    Oehler MK; Rehn M; Kristen P; Sütterlin M; Caffier H
    Anticancer Res; 1997; 17(4B):3137-40. PubMed ID: 9329620
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Male breast cancer: pathological and immunohistochemical features.
    Willsher PC; Leach IH; Ellis IO; Bell JA; Elston CW; Bourke JB; Blamey RW; Robertson JF
    Anticancer Res; 1997; 17(3C):2335-8. PubMed ID: 9245247
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epidermal growth factor receptors: status and effect on breast cancer patients.
    Mansour OA; Zekri AR; Harvey J; el-Ahmady O
    Anticancer Res; 1997; 17(4B):3107-10. PubMed ID: 9329612
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationship of membrane-bound tissue type and urokinase type plasminogen activators in human breast cancers to estrogen and epidermal growth factor receptors.
    Needham GK; Nicholson S; Angus B; Farndon JR; Harris AL
    Cancer Res; 1988 Nov; 48(22):6603-7. PubMed ID: 3141047
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An evaluation of the prognostic significance of vascular endothelial growth factor in node positive primary breast carcinoma.
    MacConmara M; O'Hanlon DM; Kiely MJ; Connolly Y; Jeffers M; Keane FB
    Int J Oncol; 2002 Apr; 20(4):717-21. PubMed ID: 11894115
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation.
    Rakha EA; Putti TC; Abd El-Rehim DM; Paish C; Green AR; Powe DG; Lee AH; Robertson JF; Ellis IO
    J Pathol; 2006 Mar; 208(4):495-506. PubMed ID: 16429394
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer.
    Tischkowitz M; Brunet JS; Bégin LR; Huntsman DG; Cheang MC; Akslen LA; Nielsen TO; Foulkes WD
    BMC Cancer; 2007 Jul; 7():134. PubMed ID: 17650314
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of a basal-like subtype of breast ductal carcinoma in situ.
    Livasy CA; Perou CM; Karaca G; Cowan DW; Maia D; Jackson S; Tse CK; Nyante S; Millikan RC
    Hum Pathol; 2007 Feb; 38(2):197-204. PubMed ID: 17234468
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of receptor activator of nuclear factor kappabeta ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathological variables.
    Cross SS; Harrison RF; Balasubramanian SP; Lippitt JM; Evans CA; Reed MW; Holen I
    J Clin Pathol; 2006 Jul; 59(7):716-20. PubMed ID: 16489180
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.